Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesQualitative or Semiquantitative ImmunoassaysCPT cpt-86408-sars-cov-2-neutralizing-antibody-screening
    Ask Trek AI about this page

    CPT 86408: SARS–CoV–2 Neutralizing Antibody Screening, Technical

    CPT code 86408 describes a laboratory technical service that screens a specimen (for example, plasma) for neutralizing antibodies to SARS–CoV–2 (the virus that causes COVID-19); the service is a laboratory antigen/antibody screening test typically performed in a clinical laboratory or reference lab and involves the technical processing, assay performance, and reporting of test results for detection of functional neutralizing antibodies.

    For related coverage guidance, see recent payer policy updates: Allergen Subcutaneous Immunotherapy (SCIT), Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policy, Allergy and Sensitivity Tests of Uncertain Efficacy.

    Customize your policy alerts

    Sign up for cpt 86408 policy alerts

    Get alerted when payer policies referencing 86408 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 6

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A 45-year-old outpatient presents for evaluation of post-infection immune response following confirmed SARS–CoV–2 infection three months prior. The clinician orders a neutralizing antibody screen to assess the presence and level of functional antibodies in plasma that can inhibit viral entry. A phlebotomy technician collects a plasma specimen and sends it to the clinical laboratory. In the lab, a medical technologist or lab analyst performs the technical neutralizing antibody assay (a virology neutralization or surrogate neutralization test) and documents results in the laboratory information system. Results are routed to the ordering provider for interpretation and potential patient counseling. Typical site of service is a hospital clinical laboratory, independent reference laboratory, or large outpatient hospital-based phlebotomy collection center. Service type: Clinical laboratory diagnostic immunology/virology testing for neutralizing antibodies to SARS–CoV–2.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    36415Collection of venous blood by venipunctureVenous specimen collection required prior to performing the neutralizing antibody assay.
    86328Antibody; immunoassay for infectious agent, qualitative or semiquantitative, single step methodAlternative immunoassay methods that may be used for SARS–CoV–2 antibody detection when neutralizing assays are not performed.
    87635Infectious agent detection by nucleic acid (e.g., SARS-CoV-2), amplified probe techniquePerformed in the clinical workflow when active infection needs to be confirmed or excluded in parallel with antibody testing.
    87426Infectious agent detection by nucleic acid, direct probe techniqueAnother molecular test option often performed alongside serologic evaluation in some clinical workflows.
    80502Drug test confirmation (e.g., mass spectrometry) — example of lab confirmation methodologyRepresents advanced laboratory confirmation techniques; analogous to how neutralization assays confirm functional antibody activity.

    Related Modifiers

    5 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    261QP2300X
    207K00000X
    207L00000X
    363LA2200X
    163WM0705X
    207Q00000X
    207QA0505X
    311Z00000X

    Related Payer Policy Updates

    Specialty: Allergy/Clinical Immunology1 / 3

    10 rows

    PolicyPayerEffective Date
    Allergen Subcutaneous Immunotherapy (SCIT)Providence Health Plan2026-11-01
    Allergy Testing, Including Selected Blood, Serum and Cellular Testing and Toxicity Testing Corporate Medical Policybcbsvermont2026-11-01
    Allergy and Sensitivity Tests of Uncertain Efficacyregence2026-10-01
    Allergy Testing and InjectionsUnitedHealthcare2026-10-01
    Allergy TestingProvidence Health Plan2026-10-01
    Diagnosis of Idiopathic Environmental IntoleranceOscar Health2026-10-01
    Allergen Testingblue cross blue shield - louisiana2026-09-15
    Allergen TestingBlue Cross Blue Shield - New Mexico2026-09-04
    Allergen Immunotherapymarylandphysicianscarempc2026-09-01
    ALLERGY TESTING / IMMUNOTHERAPYpriority_health_medicare2026-09-01

    Related Codes

    86803-QUALITATIVE-OR-SEMIQUANTITATIVE-IMMUNOASSAYS-HEPATITIS-C

    CPT 86803: Hepatitis C Antibody Immunoassay in Serum

    CPT-86000-FEBRILE-AGGLUTININS-SEROLOGIC-TEST

    CPT 86000: Febrile Agglutinins (Serologic Agglutination) Test

    CPT-86001-ALLERGEN-SPECIFIC-IGG-LABORATORY-TEST

    CPT 86001: Allergen-Specific IgG Assay, Technical Component

    CPT-86003-ALLERGEN-SPECIFIC-IGE-ASSAY-TECHNICAL

    CPT 86003: Allergen‑Specific IgE Assay Using Crude Allergen Extract

    CPT-86005-MULTI-ALLERGEN-IGE-SCREENING-QUALITATIVE

    CPT 86005: Multi-Allergen Allergen-Specific IgE Screening

    CPT-86008-ALLERGEN-COMPONENT-SPECIFIC-IGE-ASSAY

    CPT 86008: Allergen Component–Specific IgE Assay

    CPT-86015-ANTI-ACTIN-SMOOTH-MUSCLE-ANTIBODY-ASMA

    CPT 86015: Actin (Smooth Muscle) Antibody (ASMA) Immunoassay

    CPT-86021-LEUKOCYTE-ANTIBODY-IDENTIFICATION-LAB-TECHNICAL

    CPT 86021: Leukocyte Antibody Identification Laboratory Test

    CPT-86022-PLATELET-ANTIBODY-IDENTIFICATION-TECHNICAL-TEST

    CPT 86022: Platelet Antibody Detection and Identification

    CPT-86023-PLATELET-ASSOCIATED-IMMUNOGLOBULIN-DETECTION

    CPT 86023: Platelet-Associated Immunoglobulin Assay

    Showing 1–10 of 199

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.